Compare VERU & DTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | DTST |
|---|---|---|
| Founded | 1971 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 32.5M |
| IPO Year | 1990 | N/A |
| Metric | VERU | DTST |
|---|---|---|
| Price | $2.65 | $4.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 203.5K | 45.0K |
| Earning Date | 02-12-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8036.56 |
| EPS | N/A | ★ 1.89 |
| Revenue | N/A | ★ $25,529,819.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.59 |
| Revenue Growth | N/A | ★ 260.19 |
| 52 Week Low | $2.10 | $2.93 |
| 52 Week High | $14.20 | $5.44 |
| Indicator | VERU | DTST |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 32.28 |
| Support Level | $2.27 | $4.32 |
| Resistance Level | $2.49 | $5.13 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 90.60 | 18.07 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.